NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
27. November 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
13. November 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
Allsup Employment Services Bridges The Employment Gap For Spinal Cord Injury Survivors
09. Oktober 2024 12:15 ET
|
Allsup
Belleville, Illinois, Oct. 09, 2024 (GLOBE NEWSWIRE) -- As the economy fuels job opportunities, Allsup Employment Services (AES) , a Social Security-authorized Employment Network (EN), reaffirms its...
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06. September 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
23. August 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09. August 2024 16:04 ET
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11. Juni 2024 08:44 ET
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
29. Mai 2024 08:15 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and...
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25. April 2024 08:35 ET
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
19. April 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine